1 |
nuclear factor of activated T cells c1
(617 times)
|
Biochemistry (84 times)
|
RANKL (287 times) TRAP (173 times) BMMs (101 times)
|
2003 Calcineurin is a potent regulator for skeletal muscle regeneration by association with NFATc1 and GATA-2.
|
2 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1
(17 times)
|
Biochemistry (8 times)
|
RANKL (12 times) TRAP (5 times) BMMs (4 times)
|
2005 MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
|
3 |
nuclear factor of activated T cells calcineurin-dependent 1
(3 times)
|
Pharmacology (1 time)
|
RANKL (2 times) ERK (1 time) JmjC (1 time)
|
2012 JMJD5, a Jumonji C (JmjC) domain-containing protein, negatively regulates osteoclastogenesis by facilitating NFATc1 protein degradation.
|
4 |
NF for activation of T cells c1
(1 time)
|
Allergy and Immunology (1 time)
|
AP-1 (1 time) NF (1 time)
|
2005 Fos/AP-1 proteins in bone and the immune system.
|
5 |
NFAT cytoplasmic-1
(1 time)
|
Chemistry (1 time)
|
COX-2 (1 time) CREB (1 time) NFAT (1 time)
|
2017 TNFalpha Increases RANKL Expression via PGE₂-Induced Activation of NFATc1.
|
6 |
nuclear factor 1
(1 time)
|
Neoplasms (1 time)
|
BC (1 time) BM (1 time) MALAT1 (1 time)
|
2020 Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis.
|
7 |
nuclear factor calcineurin-dependent 1
(1 time)
|
Clinical Medicine (1 time)
|
RANK (1 time)
|
2021 A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor.
|
8 |
nuclear factor of T cell c1
(1 time)
|
Chemistry (1 time)
|
OPCs (1 time) OSCC (1 time) RANKL (1 time)
|
2019 A Novel, Tumor-Induced Osteoclastogenesis Pathway Insensitive to Denosumab but Interfered by Cannabidiol.
|